HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Expression of CD147 and Lewis y antigen in ovarian cancer and their relationship to drug resistance.

Abstract
The purpose of this study was to investigate the relationship between the expression of CD147 and Lewis y antigen in epithelial ovarian carcinoma tissues and resistance to chemotherapeutic drugs, and its underlying clinical significance, and to analyze the correlation between the expression of CD147 and Lewis y antigen. Ninety-two ovarian cancer patients were divided into a chemotherapeutic-drug-resistant group (34 patients) and a drug-sensitive group (58 patients). Immunohistochemical assays were used to measure CD147, and Lewis y antigen to investigate their correlation with chemotherapy resistance. Multivariate logistic regression was used to analyze the relationships between risk factors and resistance to chemotherapy in ovarian cancer. Cox's model was used to analyze the relationships between risk factors and prognosis. The proportion of tissues expressing CD147 and Lewis y antigen in the drug-resistant group were 94.12 and 91.67%, respectively, which were significantly higher than those in the sensitive group (77.59 and 60.34%, respectively). The multivariate analysis indicated that the expression of CD147 and Lewis y antigen and the pathological stage of the ovarian cancer were all independent risk factors for drug resistance. Expression of CD147 and Lewis y antigen was high in the resistant group, and they correlated positively with each other. The expression of CD147 and Lewis y antigen was significantly higher in the drug-resistant group and their expression correlated positively in the ovarian epithelium. The expression of CD147 and Lewis y antigen and the pathological stage of ovarian cancer were all independent risk factors for drug resistance and prognosis in ovarian cancer.
AuthorsJian Gao, Zhenhua Hu, Juanjuan Liu, Dawo Liu, Yanyan Wang, Mingbo Cai, Danye Zhang, Mingzi Tan, Bei Lin
JournalMedical oncology (Northwood, London, England) (Med Oncol) Vol. 31 Issue 5 Pg. 920 (May 2014) ISSN: 1559-131X [Electronic] United States
PMID24692145 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • BSG protein, human
  • Biomarkers, Tumor
  • Lewis Blood Group Antigens
  • Lewis Y antigen
  • Basigin
Topics
  • Adenocarcinoma, Clear Cell (drug therapy, metabolism, mortality)
  • Adenocarcinoma, Mucinous (drug therapy, metabolism, mortality)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Basigin (metabolism)
  • Biomarkers, Tumor (metabolism)
  • Cystadenocarcinoma, Serous (drug therapy, metabolism, mortality)
  • Drug Resistance, Neoplasm
  • Endometrial Neoplasms (drug therapy, metabolism, mortality)
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoenzyme Techniques
  • Lewis Blood Group Antigens (metabolism)
  • Neoplasm Grading
  • Neoplasm Staging
  • Ovarian Neoplasms (drug therapy, metabolism, mortality)
  • Prognosis
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: